|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0016360,
umls-concept:C0023413,
umls-concept:C0023981,
umls-concept:C0027627,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0150369,
umls-concept:C0178602,
umls-concept:C0201734,
umls-concept:C0332174,
umls-concept:C0439743,
umls-concept:C0443252,
umls-concept:C0555952,
umls-concept:C1274040,
umls-concept:C2698650
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1998-5-12
|
|
pubmed:abstractText |
A relationship between fluorouracil (5-FU) dose and response has been previously shown in advanced colorectal cancer. In a previous study with 5-FU stepwise dose escalation in a weekly regimen, and pharmacokinetic monitoring, we defined a therapeutic range for 5-FU plasma levels: 2,000 to 3,000 microg/L (area under the concentration-time curve at 0 to 8 hours [AUC0-8], 16 to 24 mg x h/L). The current study investigated 5-FU therapeutic intensification with individual dose adjustment in a multicentric phase II prospective trial.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AlleaumeCC,
pubmed-author:Boisdron-CelleMM,
pubmed-author:BurtinPP,
pubmed-author:CailleuxP EPE,
pubmed-author:Danquechin-DorvalEE,
pubmed-author:DelvaRR,
pubmed-author:DumesnilYY,
pubmed-author:FetzSS,
pubmed-author:GamelinEE,
pubmed-author:GeslinJJ,
pubmed-author:GestaPP,
pubmed-author:GoudierM JMJ,
pubmed-author:LarraFF,
pubmed-author:LortholaryAA,
pubmed-author:MaigreMM,
pubmed-author:MaillartPP,
pubmed-author:MailletM LML,
pubmed-author:Person-JolyM CMC,
pubmed-author:PiconLL,
pubmed-author:RegimbeauCC,
pubmed-author:RobertJJ,
pubmed-author:SiraAA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1470-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9552054-Adenocarcinoma,
pubmed-meshheading:9552054-Adult,
pubmed-meshheading:9552054-Aged,
pubmed-meshheading:9552054-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9552054-Area Under Curve,
pubmed-meshheading:9552054-Colonic Neoplasms,
pubmed-meshheading:9552054-Female,
pubmed-meshheading:9552054-Fluorouracil,
pubmed-meshheading:9552054-Humans,
pubmed-meshheading:9552054-Leucovorin,
pubmed-meshheading:9552054-Male,
pubmed-meshheading:9552054-Middle Aged,
pubmed-meshheading:9552054-Rectal Neoplasms,
pubmed-meshheading:9552054-Survival Analysis
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.
|
|
pubmed:affiliation |
Service d'Oncologie Médicale et de Pharmacologie Clinique, Centre Paul Papin, Angers, France. cppapin@unimedia.rf
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
